BIHi008-A
Donor information | |
|---|---|
| Gender: | Female |
| Age: | 60-64 |
Disease status | |
| Disease: | focal segmental glomerulosclerosis |
General information | |
| Depositor: | Berlin Institute of Health |
| Cell line name: | BIHi008-A |
| Cell line alternative names: | - |
| Biosamples ID: | SAMEA104387976 |
| hPSCreg name: | BIHi008-A |
| Derivation country: | Germany |
-
Derivation
Derivation
Primary cell type: Peripheral blood mononuclear cell Tissue collection year: 2016 Reprogramming method
Vector type: Non-integrating Vector: Sendai virus Gene list: - KLF4
- MYC
- POU5F1
- SOX2
Is the reprogramming vector detectable: No Merthods used: pcr Derivation
Xeno free conditions: no Derived under gmp: no Available as clinical grade: no -
Culture conditions
Culture Conditions
Surface coating: Matrigel/Geltrex Passage method: Enzyme-free cell dissociation / EDTA O2 concentration: 5% CO2 concentration: 5% Culture medium: Essential 8™ Passage Number banked (pre-EBiSC): 15 No. Vials banked (pre-EBiSC): 35 -
Characterization
Characterization
Analysis of Undifferentiated Cells
Marker expression: Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles TRA 1-60 Yes POU5F1 (OCT-4) Yes SSEA-4 Yes NANOG Yes Differentiation potency
Ectoderm: Ectoderm In vivo teratoma
In vitro directed differentiation
Endoderm: Endoderm In vivo teratoma
In vitro directed differentiation
Mesoderm: Mesoderm In vivo teratoma
In vitro directed differentiation
Microbiology / Virus Screening
HIV 1: Negative HIV 2: Negative Hepatitis B: Negative Hepatitis C: Negative Mycoplasma: Negative -
Genotyping
Genotyping
Karyotyping
Cell line karyotype: 46,XX Karyotyping method: KaryoLite BoBs Genotyping
Genome-wide analysis: SNP typing array
At European Collection of Authenticated Cell Cultures (ECACC)
Restocking
Cell Line Information Pack
A Cell Line Information Pack (CLIP) is created to communicate cell line specific information relating to restrictions on use to a user accessing cell lines from EBiSC. A CLIP contains information about a cell line including any specific third party obligations (TPOs) relating to, for example, intellectual property (IP) or the donor consent which affect the use of the cell line.